BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
Article content
Article content
Data underscore strength of emerging breast cancer pipeline as part of BeOne's global transformation with next wave of innovation
Article content
SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure.
Article content
'Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,' said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne. 'These early results highlight the strong potential of our B7-H4-targeting ADC and CDK2 inhibitor to address critical gaps in breast cancer treatment. Alongside our advancing CDK4 inhibitor, they represent just the beginning of a pipeline built on targeted, biology-driven innovation. As we debut our new identity as BeOne, this milestone reflects the momentum behind our science and our commitment to delivering impactful therapies to cancer patients worldwide.'
Article content
BeOne is advancing a robust pipeline of differentiated investigational medicines for breast cancer that may both effectively combat the disease and potentially improve quality of life for patients receiving treatment.
Article content
BeOne presented initial results of the ongoing first-in-human, Phase 1a dose escalation study of BG-C9074 monotherapy in 78 patients with advanced solid tumors, of which more than a quarter were breast cancer patients. BG-C9074, an investigational topoisomerase I inhibitor ADC that targets the B7-H4 protein, which is broadly expressed in breast and gynecologic cancers, is designed with an innovative drug linker to deliver a potent cancer-killing drug directly to the cancer cells.
Article content
With limited follow-up among the 56 efficacy-evaluable patients, preliminary clinical responses were observed at multiple dose levels across various tumor types without selection for B7-H4 expression in these heavily pretreated patients. Confirmed overall response rate (ORR) was 16.1% (9/56; 95% CI: 7.6%–28.3%), with 9 confirmed partial responses; unconfirmed ORR was 25.0% (14/56; 14.4%-38.4%) (n=14 partial responses). Confirmed disease control rate (DCR) was 73.2% (59.7%-84.2%) and confirmed clinical benefit rate (CBR) was 17.9% (8.9%-30.4%). Pharmacokinetics (PK) were observed to be approximately dose-proportional across dose levels.
Article content
BG-C9074 showed a manageable safety and tolerability profile in patients with B7-H4 advanced solid tumors, including breast cancer. There were 5 dose-limiting toxicities (DLTs) reported among 3 dose levels, all related to treatment: grade 3 fatigue (n=1); grade 3 febrile neutropenia (n=2); and grade 4 platelet count decreased (n=2). The most common treatment-emergent adverse events (TEAEs) were nausea, fatigue, and neutropenia*. The most common grade ≥3 TEAEs were neutropenia and thrombocytopenia†. There were no TEAEs leading to treatment discontinuation or death.
Article content
Dose-escalation data from the first-in-human, Phase 1a study of a novel CDK2 inhibitor, BG-68501, were presented as a poster today. BG-68501 is designed to address elevated CDK2 activity as well as cyclin E1-driven upregulation, two key resistance mechanisms that often limit the effectiveness of CDK4/6 inhibitors in treating HR+/HER2- breast cancer. CDK inhibitors target checkpoint proteins that control cell division to stop the growth of cancer cells.
Article content
A total of 57 enrolled patients with advanced solid tumors, including 19 patients with HR+/HER2- metastatic breast cancer, received BG-68501 as monotherapy or in combination with fulvestrant in escalating dose cohorts (all received prior CDK4/6i).
Article content
Of the 37 efficacy-evaluable patients (all with monotherapy), unconfirmed overall response rate (ORR) was 5.4% (2/37; 95% CI: 0.7%–18.2%). Two extensively pretreated patients (5.4%) experienced unconfirmed partial response (PR), 15 patients (40.5%) had stable disease (SD), 15 patients (40.5%) had progressive disease (PD), and 5 patients (13.5%) were not evaluable/not assessed. Of the 2 patients with PR, both were breast cancer patients, and one was ongoing with treatment at the time of data cutoff, while the other had discontinued treatment. Unconfirmed clinical benefit rate (CBR) was 8.1% (3/37; 95% CI: 1.7%-21.9%) and unconfirmed disease control rate (DCR) was 45.9% (17/37; 95% CI: 29.5%-63.1%). BG-68501 demonstrated a linear PK profile consistent with preclinical data and signs of pharmacodynamic responses.
Article content
BG-68501 demonstrated a manageable safety and tolerability profile, with no DLTs observed to date during dose escalation. The most common TEAEs were vomiting, nausea, and fatigue, and TEAEs leading to treatment discontinuation occurred in 4 patients (7%) across all dose levels. There were no TEAEs leading to death.
Article content
The data support continued development of BG-68501 as a next-line option for tumors with CDK2 dependency. ( NCT06257264)
Article content
For additional information about our presence at the 2025 ASCO Annual Meeting, please visit our meeting hub: congress.beonemedicines.com.
Article content
BeOne will host an investor R&D Day on June 26 at 8:30 am ET covering its deep and broad global innovation pipeline and platforms, as well as the Company's vision, differentiated capabilities, and value creation drivers. A live webcast will be accessible from the investors section of BeOne's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, or https://sseir.beonemedicines.com. An archived replay will be available for 90 days following the event.
Article content
BeOne is advancing a robust portfolio of investigational medicines for breast cancer, including three molecules in clinical development – two cyclin-dependent kinase (CDK) inhibitors, BGB-43395, a CDK4 inhibitor, and BG-68501, a CDK2 inhibitor, and an antibody-drug conjugate (ADC), BG-C9074. BeOne also plans to evaluate the potential of BCL2 inhibition in breast cancer, with next-generation BCL2 inhibitor, BGB-21447, expected to begin clinical testing in solid tumor indications soon. Multispecific antibodies and targeted protein degraders with potential applications in breast cancer are among the preclinical assets being developed.
Article content
About Breast Cancer
Article content
Breast cancer accounts for close to one in four cancer cases and one in six cancer deaths in women worldwide. 1 Globally, breast cancer is the second most common cancer and the fourth highest cause of cancer mortality as well as the leading cause of cancer death in women. 1 More than 2.3 million patients were diagnosed with breast cancer in 2022, and over 666,000 deaths were reported globally. 1 Approximately two-thirds of breast cancer cases are the HR+/HER2- subtype. 2
Article content
About BeOne
Article content
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
Article content
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential of BeOne's B7-H4-targeting ADC and CDK2 inhibitor to address critical gaps in breast cancer treatment; the ability of BeOne to deliver impactful therapies to cancer patients worldwide; the ability of BeOne's pipeline to effectively combat breast cancer and improve quality of life for patients; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
Article content
*Neutropenia was defined by a custom MedDRA basket with neutropenia and neutrophil count decrease preferred terms.
Article content
†Thrombocytopenia was defined by a custom MedDRA basket with thrombocytopenia and platelet count decreased preferred terms.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
Prediction: 2 Artificial Intelligence (AI) Stocks That Will Be Worth More Than Palantir Within 1 Year
Artificial intelligence (AI) has been the driving force behind the stock market's gains since the release of ChatGPT in November 2022. Few companies have benefited more from the advancements and excitement around generative AI than Palantir Technologies (NASDAQ: PLTR). Palantir's financial results have been fantastic as it expands its customer base and use cases within enterprises. Those results were boosted by Palantir's Artificial Intelligence Platform (AIP), which makes it easy to glean new insights from big data sets. As a result, the company's stock has climbed 1,630% since December 2022 and sports a market cap of over $300 billion, as of this writing. Palantir is now one of the most valuable companies in the world. But a couple of other AI innovators could overtake it within the next year. Here are two AI stocks I think will be worth more than Palantir in the near future. The biggest challenge for Palantir stock As mentioned, Palantir has produced excellent financial results. Its AIP makes it easier for nontechnical users to take advantage of its core software, which helps businesses and governments make decisions and gain insights based on large, often disparate datasets. As a result, more businesses can use Palantir, and more people and departments within each business can use it. That's led to strong revenue growth over the last few years. Revenue grew 39% year over year in the first quarter. Moreover, as a software company, Palantir's able to produce tremendous operating leverage, since the marginal cost of taking on another customer is minimal. As a result, operating margin expanded to 44% last quarter. Management expects to produce that level of profitability for the full year as well. There's no doubt Palantir's producing excellent operating results. The challenge for the stock is its valuation. Shares currently trade for more than 75 times management's outlook for 2025 revenue. Its enterprise value is 175 times analyst expectations for earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months. Analysts put a median price target of $100 per share on Palantir, a 24% drop from its current price. Only a handful rate the stock "overweight" or "buy." To say that it's expensive may be an understatement. Meanwhile, these two stocks look undervalued despite the potential for AI to help grow their businesses substantially over the next few years. 1. Salesforce Salesforce (NYSE: CRM) is looking to take its dominant position in enterprise software solutions for sales and marketing, customer service, and data management, and help businesses harness the power of AI within those systems. Its solution is called Agentforce, which rolled out late last year. Agentforce allows businesses to use their data and systems to create AI agents that can make decisions and take actions without human intervention. The company has signed around 8,000 Agentforce contracts as of the end of May. It's producing annual recurring revenue of around $100 million. When combined with its data management solutions, it's a $1 billion business just a few months after launching. That said, it's still just a small part of Salesforce's overall business. Management expects sales to top $41 billion this year, with an operating margin of 34%. That's supported by stable subscription revenue from its core enterprise software offerings. Despite strong earnings results and raising its full-year outlook last month, investors sent the stock price lower following its most recent earnings report. There could be a couple of reasons. Management announced the acquisition of Informatica for $8 billion, increasing execution risk for the business. If the acquisition doesn't meaningfully accelerate its data management business, investors could see it as a waste of money. The other detail that came in below expectations was its remaining performance obligations. But strong uptake in Agentforce and management increasing its full-year guidance should offset the weakness there. Salesforce stock currently trades for just 6 times management's revenue guidance. Its forward P/E ratio of just 23 looks very attractive. Analysts seem to agree, putting a median price target of $355 on the stock, a 35% upside from its price as of this writing. That could put the company's value well over $300 billion within a year. 2. Adobe Adobe (NASDAQ: ADBE) has taken innovations in AI over the last few years and applied them to its own products across both its creative suite of software (Photoshop, Lightroom, Premiere Pro, etc.) and its marketing, analytics, and productivity software (Acrobat, e-signing, etc.). It touts its FireFly model as "commercial safe," meaning it was trained on stock images and data that users can freely publish to their own websites and other online accounts. Adobe's AI integrations have helped it increase pricing for its software, but they also provide new opportunities to bring in customers. It integrated AI with Adobe Express, its online creative service, and it's seen an uptick in new customer accounts and conversion from free accounts to paid accounts. It also introduced GenStudio, which combines its creative and marketing software and allows users to create new ad campaigns and managing existing ones using natural language prompts. Management says it ended the first quarter with $125 million in annual recurring revenue, directly attributable to AI services. It expects that number to double by year-end. But more impressive is the $3.5 billion in AI-influenced annual recurring revenue across its existing portfolio. That stems from increased retention rates and higher revenue per user. That's already a significant chunk of the businesses' $23 billion annual revenue, and it's growing quickly. Many investors see generative AI as a significant threat to Adobe's creative software. But Adobe is fully entrenched in the creative business, and there's a strong network effect and high switching costs involved with leaving the ecosystem. Understanding how to use Adobe's creative software is practically a requirement for any designer, photographer, or film editor. As Adobe continues to advance its own AI capabilities, it stands to strengthen its competitive moat. Adobe stock trades for about 7 times management's estimate for 2025 revenue. Its forward P/E sits below 20. Meanwhile, management's outlook for the next three years suggests double-digit revenue growth while exhibiting operating leverage. At its current price, the stock looks like a bargain. The median price target on Wall Street is $477.50, implying 19% upside from the stock price, as of this writing. I believe the upside could be even greater, based on strong earnings growth and multiple expansion, and the company could be worth closer to $250 billion within a year. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
an hour ago
- Globe and Mail
Trump doubles down on steel, aluminum tariffs
On Tuesday, U.S. President Donald Trump signed a new executive order that raised tariffs on steel and aluminum from 25 per cent to 50 per cent. One Canadian steel producer said this means that their American business is now 'unviable'. Jason Kirby is a staff reporter for The Globe's Report on Business section. He explains why these higher steel and aluminum tariffs could mean higher prices on nearly everything, and what may have contributed to Trump's escalation. Questions? Comments? Ideas? Email us at thedecibel@
Globe and Mail
an hour ago
- Globe and Mail
Disney Has Another Huge Hit at the Box Office. Is It Finally Time to Buy?
Walt Disney (NYSE: DIS) might be the top name in entertainment, but that doesn't automatically mean its stock is always in good shape. It's taken a pounding over the past few years as the company goes from one problem to the next, and it's down 44% from its all-time highs. Are things starting to stabilize? The company reported solid results for the 2025 fiscal second quarter (ended March 29), and its newest film release, the live-action Lilo and Stitch, had a fantastic opening weekend. Is now the time to buy on the rebound? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » What's happening at Disney? Disney is a huge media and entertainment giant with many working pieces. Today, it divides its business into three segments: entertainment, sports, and experiences. Entertainment covers its content, including streaming, film releases, and network TV. Sports is its sports-related content, and experiences covers parks, as well as other experiences like cruises and resorts. When everything goes well, Disney is an unmatched powerhouse. But with so many moving parts, the whole gets weighed down by any disruption. Fortunately, in the most recently reported quarter, there was success all around. Total revenue was up 7% year over year, with increases in all three segments. Operating income more than doubled to $3.1 billion, driven by increases in streaming, which had been holding back profits for too long. Streaming subscriptions increased by 2.5 million from the previous quarter, and Disney+ is now firmly profitable and growing. Even linear networks, the traditional TV channels that are on the decline, managed a small operating profit increase in the quarter, and the weakest segment was sports, which reported a drop in operating income. Disney is still figuring out the sports piece as it transitions from a cable focus to a streaming one, and it recently said that it's offering ESPN as a full, direct-to-consumer offering starting this fall. It was just announced that Disney is acquiring popular sports show Inside the NBA, and it's aiming to keep its go-to status and attract paid viewers to the new venture. Back to film success Disney felt some pressure with the Hollywood strikes two years ago, pushing back film production and delaying some releases. It bounced back last year, ending 2024 with the highest-grossing film worldwide, Inside Out 2, as well as the No. 3 spot, Moana 2, and the No. 6 spot, Mufasa: The Lion King. It's doing incredibly so far in 2025, with exactly half of the top 10 highest-grossing films domestically. The most recent release, Lilo and Stitch, came out on Memorial Day weekend and is already the second-highest-grossing film of the year, with $279 million in domestic box office sales. It shattered records to take in the highest four-day Memorial Day weekend sales ever, and it's already picked up more than $600 million in sales worldwide. Like Lilo and Stitch, many of the recent hits and upcoming releases depend on the well-worn Disney model of creating franchises and churning out content based on beloved characters. Every single one of its top 10 releases so far this year is a remake or sequel of sorts. Disney has another six films set to come out this year, of which only one is a new franchise. The other five include the third installment in the Avatar movies, and the first two Avatar movies hold the No. 1 and No. 3 spots for highest-grossing films ever. Incidentally, the No. 2 spot, Avengers: Endgame, belongs to a Disney franchise, too. Disney has many films already slated for release in 2026 and further out, including the fourth Avatar film, the next Frozen film, etc. These are almost guaranteed to be huge box office hits, and the creative teams spin these franchises into more content for streaming, as well as for use in products and theme parks. Should you buy Disney stock? Disney is in a good place today, with a profitable streaming business, hit films, and an upcoming sports launch. It just announced a new round of layoffs, and although that could contain a warning, the market usually greets layoffs enthusiastically, since a leaner organization typically leads to a stronger bottom line. I wouldn't put too many eggs into Disney's basket yet, but where it's holding today, Disney looks like it's staged for a comeback, and its stock should reflect that. Should you invest $1,000 in Walt Disney right now? Before you buy stock in Walt Disney, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Walt Disney wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
